NCT05201326

Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma

An Open and Single-arm Prospective Clinical Study of the Safety and Efficacy of Irinotecan and Bevacizumab Combined With Re-radiotherapy in the Treatment of Recurrent Glioblastoma

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I study to observe the safety and efficacy of irinotecan and bevacizumab combined with re-radiotherapy in the treatment of recurrent glioblastoma. The study will provide a higher level of clinical evidence-based evidence for the clinical treatment of recurrent GBM, and fill the guidelines for the treatment of recurrent GBM.

Conditions

• Recurrent Glioblastoma

Interventions

Type	Name	Description
DRUG	Bevacizumab，Irinotecan and Re-radiotherapy	All patients with recurrent glioblastoma will accept irinotecan and bevacizumab combined with re-radiotherapy .

Timeline

• Start date: 2021-12-22
• Primary completion: 2022-12-20
• Completion: 2024-12-20
• First posted: 2022-01-21
• Last updated: 2022-01-21

Locations

1 site across 1 country: China